Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

Deconstructing Myogen's market cap

Nature Biotechnology volume 24, pages 227–228 (2006)Cite this article

The best-performing stock from 2005 was a prime example of how biotech stocks are not as capricious as they may seem.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Lone Tree, Colorado

    John Ransom

Authors
  1. John Ransom
    View author publications

    You can also search for this author in PubMed Google Scholar

Related links

Related links

Web links

Myogen

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ransom, J. Deconstructing Myogen's market cap. Nat Biotechnol 24, 227–228 (2006). https://doi.org/10.1038/nbt0306-227

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0306-227

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing